Alzheimer's disease and Down's syndrome: Treating two paths to dementia

Autoimmunity Reviews

Volumn 12, Issue 6, 2013, Pages 670-673

  Weksler, Marc E ^a   Szabo, Paul ^a   Relkin, Norman R ^a   Reidenberg, Marcus M ^a   Weksler, Babette B ^a   Coppus, Antonia M W ^b,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Clearing amyloid beta peptide; Down's syndrome; Inhibiting synthesis of amyloid beta peptide

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; BABINEUZUMAB; IMMUNOGLOBULIN; SOLANEZUMAB; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM; DOWN SYNDROME; DRUG INDUSTRY; HUMAN; IMMUNOTHERAPY; NONHUMAN; PASSIVE IMMUNIZATION; PROTEIN SYNTHESIS; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CENTRAL NERVOUS SYSTEM; DEMENTIA; DOWN SYNDROME; HUMANS;

EID: 84877058407     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.10.013     Document Type: Review

References (29)

1. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease. Science 2002, 297:353-356.
2. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiatr 1907, 64:146-148.
3. Glenner G.G., Wong C.W. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984, 122:1131-1135.
4. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 1985, 82:4245-4249.
5. Down J.L.H. Observations on an ethnic classification of idiots. Clinical lecture reports, London Hospital 1866, 3:259-262.
6. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Nobel Lecture December 1985.
7. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995, 373:523-527.
8. Schenk D., Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., et al. Immunization with amyloid-beta [U+F020]attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
9. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
10. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
11. Nicoll J.A., Barton E., Boche D., Neal J.W., Ferrer I., Thompson P., et al. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 2006, 65:1040-1048.
12. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000, 6:916-919.
13. Britschgi M., Olin C.E., Johns H.T., Takeda-Uchimura Y., LeMieux M.C., Rufibach K., et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci U S A 2009, 106:12145-12150.
14. Relkin N.R., Szabo P., Adamiak B., Burgut T., Monthe C., Lent R.W., et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009, 30:1728-1736.
15. Bateman R.J., Munsell L.Y., Morris J.C., Swarm R., Yarasheski K.E., Holtzman D.M. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 2006, 12:856-861.
16. Mawuenyega K.G., Sigurdson W., Ovod V., Munsell L., Kasten T., Morris J.C., et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010, 330:1774-1776.
17. Cramer P.E., Cirrito J.R., Wesson D.W., Lee C.Y., Karlo J.C., Zinn A.E., et al. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 2012, 335:1503-1506.
18. Kapadia M., Sakic B. Autoimmune and inflammatory mechanisms of CNS damage. Prog Neurobiol 2011, 95:301-333.
19. Sardi F., Fassina L., Venturini L., Inguscio M., Guerriero F., Rolfo R., et al. Alzheimer's disease, autoimmunity and inflammation. Alzheimer's disease, autoimmunity and inflammation. Autoimmun Rev 2011, 11:149-153.
20. Jervis G.A. Some observations on the problem of heredity and environment in mental retardation. Proc Annu Meet Am Psychopathol Assoc 1967, 56:262-269.
21. Lejeune J., Turpin R., Gautier M. Chromosomic diagnosis of mongolism. Arch Fr Pediatr 1959, 16:962-963.
22. Prasher V.P., Farrer M.J., Kessling A.M., Fisher E.M., West R.J., Barber P.C., et al. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol 1998, 43:380-383.
23. Coppus A.M., Evenhuis H.M., Verberne G.J., Visser F.E., Oostra B.A., Eikelenboom P., et al. Survival in elderly persons with Down syndrome. J Am Geriatr Soc 2008, 56:2311-2316.
24. Coppus A.M., Schuur M., Vergeer J., Janssens A.C., Oostra B.A., Verbeek M.M., van Duijn C.M. Neurobiol Aging 2012, 33(9):1988-1994. [Epub 2011 Sep 29]. 10.1016/j.neurobiolaging. 2011.08.007.
25. Conti E., Galimberti G., Piazza F., Raggi M.E., Ferrarese C. Increased soluble APPalpha, Abeta 1=42, and anti-Beta 1-42 antibodies in plasma from Down syndrome patients. Alzheimer Dis Assoc Disord 2010, 24:96-100.
26. Netzer W.J., Powell C., Nong Y., Blundell J., Wong L., Duff K., et al. Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model. PLoS One 2010, 3:e10943.
27. He G., Luo W., Li P., Remmers C., Netzer W.J., Hendrick J., et al. Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 2010, 467:95-98.
28. Isobe Y., Sugimoto K., Masuda A., Hamano Y., Oshimi K. Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate. Intern Med J 2009, 39:408-411.
29. Sutcliffe J.G., Hedlund P.B., Thomas E.A., Bloom F.E., Hilbush B.S. Peripheral reduction of beta-amyloid is sufficient to reduce brain beta-amyloid: implications for Alzheimer's disease. J Neurosci Res 2011, 89:808-814.